![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 1.83% | 27.75 | 27.50 | 28.00 | 27.75 | 27.25 | 27.25 | 1,058,943 | 14:49:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.65 | 185.4M |
TIDMVENN
RNS Number : 2206L
Venn Life Sciences Holdings PLC
08 January 2016
8 January 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Year End Update
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that revenues for full year to 31 December 2015 are expected to be at least double the previous year (2014: EUR4.9m). With a cash position at year end of EUR3.4m and the business now generating free cashflows Venn is well funded for future growth and well positioned to deliver further international expansion.
This strong performance has been delivered through continued success in winning enterprise level contracts, facilitated by a growing reputation for delivering excellence and ongoing expansion of our international coverage and service capabilities.
Commenting on the Year End Update, CEO of Venn Life Sciences, Tony Richardson stated: "We have now more than doubled our book of business in successive years and built a strong foundation on which we can deliver further growth. The addition of drug development and early phase capabilities into our service offering will enable us to capture greater market share in 2016 and truly differentiate our position in the market."
Enquiries:
Venn Life Sciences Holdings www.vennlifesciences.com Plc Tony Richardson, Chief Executive Tel: +353 154 99 341 Officer Jonathan Hartshorn, Chief Financial Tel: +353 153 93 269 Officer Orla McGuinness, Marketing Tel: +353 153 93 269 Manager Zeus Capital (Nominated Adviser Tel :+44(0)20 3829 and Joint Broker) 5000 Andrew Jones / Phil Walker Domnic Wilson / Alex Davis Hybridan LLP (Joint-Broker) Claire Louise Noyce Tel: 020 3764 2341 Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
For more information about the Company, please visit: www.vennlifesciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTAKODQCBKDCDK
(END) Dow Jones Newswires
January 08, 2016 02:01 ET (07:01 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions